Miconazole therapy for keratomycosis.
I treated seven patients with keratomycosis (four with Candida infections and three with Aspergillus infections) with topical and subconjunctival miconazole. Progressive corneal ulceration stopped in each case, and clinical evidence of corneal infection disappeared. Posttreatment visual acuities were at least as good as (and usually better than) pretreatment visual acuities. Superficial punctate keratitis was associated with prolonged (one to two weeks) hourly instillation of miconazole, but there was no evidence of serious ocular toxicity.
D000328:Adult; D000368:Aged; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D003316:Corneal Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007634:Keratitis / Q000188:drug therapy; D007654:Ketoconazole; D008297:Male; D008825:Miconazole / Q000627:therapeutic use*; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D014792:Visual Acuity / Q000187:drug effects
D007093:Imidazoles; D010879:Piperazines; D008825:Miconazole; D007654:Ketoconazole